2830 In addition to its glucose- and weight-lowering efficacy, semaglutide, when used as add-on standard care in patients with T2DM and high cardiovascular disease, was found to be associated with significantly lower risk of cardiovascular death, nonfatal myocardial infarction, stroke and new or worsening nephropathy compared to placebo
The clinical trial data shows results that are closely comparable between the two formulations
Injecting expired semaglutide bypasses these assurances and could result in infection, allergic reaction, or treatment failure
Pistacia lentiscus supplementation led to significant reductions in LDL levels and ratios in the intervention group, suggesting its potential as a non-pharmacological intervention to mitigate oxidative stress in IBD
PMID: 34884978 Martini, H
De Simone, A